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Abstract
Background: Net survival is the most common measure of cancer prognosis and has been used to study
differentials in cancer survival between ethnic or racial population subgroups. However, net survival ignores
competing risks of deaths and so provides incomplete prognostic information for cancer patients, and when
comparing survival between populations with different all-cause mortality. Another prognosis measure, “crude
probability of death”, which takes competing risk of death into account, overcomes this limitation. Similar to
net survival, it can be calculated using either life tables (using Cronin-Feuer method) or cause of death data
(using Fine-Gray method). The aim of this study is two-fold: (1) to compare the multivariable results produced
by different survival analysis methods; and (2) to compare the Cronin-Feuer with the Fine-Gray methods, in estimating
the cancer and non-cancer death probability of both Indigenous and non-Indigenous cancer patients and the Indigenous
cancer disparities.
Methods: Cancer survival was investigated for 9,595 people (18.5% Indigenous) diagnosed with cancer in the Northern
Territory of Australia between 1991 and 2009. The Cox proportional hazard model along with Poisson and Fine-Gray
regression were used in the multivariable analysis. The crude probabilities of cancer and non-cancer methods were
estimated in two ways: first, using cause of death data with the Fine-Gray method, and second, using life tables with the
Cronin-Feuer method.
Results: Multivariable regression using the relative survival, cause-specific survival, and competing risk analysis produced
similar results. In the presence of competing risks, the Cronin-Feuer method produced similar results to Fine-Gray in the
estimation of cancer death probability (higher Indigenous cancer death probabilities for all cancers) and non-cancer death
probabilities (higher Indigenous non-cancer death probabilities for all cancers except lung cancer and head and neck
cancers). Cronin-Feuer estimated much lower non-cancer death probabilities than Fine-Gray for non-Indigenous patients
with head and neck cancers and lung cancers (both smoking-related cancers).
(Continued on next page)
* Correspondence: vincent.he@menzies.edu.au
1Menzies School of Health Research, Charles Darwin University, PO Box
41096, Casuarina, NT 0811, Australia
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
He et al. Population Health Metrics  (2017) 15:1 
DOI 10.1186/s12963-016-0118-9
(Continued from previous page)
Conclusion: Despite the limitations of the Cronin-Feuer method, it is a reasonable alternative to the Fine-Gray method
for assessing the Indigenous survival differential in the presence of competing risks when valid and reliable subgroup-
specific life tables are available and cause of death data are unavailable or unreliable.
Keywords: Survival analysis, Indigenous Australians, Competing risks, Fine-Gray model, Net survival, Crude probability of
death, Cancer prognosis, Life tables, Smoking, Cause of death data
Background
In Australia, Indigenous cancer patients have lower net
survival than non-Indigenous patients [1], but there is
limited information about whether Indigenous cancer
patients also have higher probability of non-cancer
death, given the Indigenous population’s higher preva-
lence of chronic diseases and much higher all-cause
mortality rates [2].
Net survival is the measure most commonly used to
compare cancer prognosis in different populations
(e.g., between nations, regions, or racial/ethnic
groups) [1, 3–9] because net survival removes the ef-
fect of non-cancer deaths (which may vary between
populations because of different all-cause mortality
rates [10]) and measures the hypothetical scenario in
which patients are only able to die of their cancer.
However, this is a disadvantage of net survival for
patients and clinicians who, when considering the
treatment options and weighing up the benefits,
drawbacks, and toxicities of cancer therapy, want to
know about actual prognosis: what is the chance of
dying (from cancer or any cause) compared with the
chance of surviving [5, 9, 10]? This is particularly
important for Indigenous Australians, and other pop-
ulations who also have higher probability of death
from “competing” (i.e., non-cancer) causes [3, 5, 10].
For this purpose, “crude probability of death” is a more
appropriate measure of prognosis than net survival be-
cause it takes competing risk into account and enables
us to identify whether survival disparities are caused by
cancer deaths, non-cancer deaths, or both. Crude prob-
ability of cancer death (hereafter referred to as “cancer
death probability”) is the probability of death from
cancer in the presence of other causes; while crude
probability of non-cancer death (hereafter referred to as
“non-cancer death probability”) is the probability of
death from other causes in the presence of cancer.
Both net survival and crude probability of death can
be estimated in two different ways: one based on cause
of death to classify each death as a cancer or non-cancer
death, the other based on life tables to compare the
number of deaths in cancer patients with the number
“expected” based in total population mortality rates
(Table 1). Cause of death data can be used to estimate
net survival by calculating the cause-specific survival
proportion or to estimate crude probabilities of cancer
and non-cancer death using the Fine-Gray competing
risks model. Similarly, life tables can be used to calculate
net survival using the relative survival method or crude
probabilities of cancer and non-cancer deaths using the
Cronin-Feuer method.
Life table-based methods are commonly used for
comparing cancer survival between population groups
because of deficiencies in cause of death data; such defi-
ciencies may be greater for disadvantaged subgroups.
However, life tables are often not available for such
subgroups because of uncertainty about population
estimates and absent or incomplete identification of
subgroup members in death registrations. Australia has
high-quality cause of death data but incomplete life
tables for the Indigenous population, except for the
Northern Territory (NT) where Indigenous Australians
are very high prevalence (30% of the NT population
compared to 2–4% in other states) and consequently are
accurately identified in deaths data and have reliable
population estimates [11]. Indigenous status is also re-
corded with a high degree of accuracy in the NT Cancer
Register (NTCR) [12]. The availability of high-quality
data for the Indigenous population and Indigenous can-
cer patients puts the NT in the best position to compare
the implications of using the Cronin-Feuer and Fine-
Gray methods to assess the Indigenous disparities in
cancer and non-cancer deaths.
The aim of this study is two-fold: (1) to compare the
multivariable results (i.e., Indigenous differentials) pro-
duced by relative survival, cause-specific survival, and
competing risk (Fine-Gray) survival analysis methods;
and (2) to compare the Cronin-Feuer with the Fine-Gray
survival analysis methods, in estimating the cancer and
non-cancer death probability of both Indigenous and
non-Indigenous cancer patients and the Indigenous




Cancer registrations data for all NT residents diagnosed
with cancer between 1 January 1991 and 31 December
2009 was obtained from the NTCR for the following data
items: sex; date of birth; Indigenous status; remoteness of
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residence (urban or remote); date of diagnosis; cancer site,
coded according to the International Classification of Dis-
eases 10 (ICD-10); date of death; and underlying cause of
death. Vital status was verified by matching the NTCR
dataset to the National Death Index for deaths occurring
up to 31 December 2011 (at the time of analysis, cause of
death data were only available up until 31 December
2011). For the survival analysis of site-specific cancers,
female breast (C50), colorectal (C18-20), lung (C33-34),
and head and neck (C1-C14 & C30-32) cancers were
chosen because there were sufficient numbers of both
Indigenous and non-Indigenous cases for the analysis, and
they are Australia’s designated national “priority” cancers
[13] (except head and neck cancers). Head and neck
cancer was chosen as it is a major cause of morbidity and
mortality associated with smoking.
Statistical analysis
The censoring date for the survival analysis was 31
December 2011. The survival time for cancer patients
who died on the day of diagnosis was counted as half
a day.
Relative survival was calculated using the “strs” proce-
dures [14] of Stata, in which the expected survival was
estimated using the Ederer II method [15]. The NT non-
Indigenous population has very high migration to and
from other parts of Australia and similar health status
and mortality to Australians generally, so life tables
for the relevant years (1991–2009) for the total Australian
population were used for non-Indigenous cancer patients.
Life tables for the NT Indigenous population (for which
deaths and population data are more reliable than for
Indigenous people in other states and territories [11])
were used for the Indigenous cancer patients. Cancer and
non-cancer death probabilities were calculated in two
ways: the Fine-Gray model used cause of death informa-
tion from the cancer cohort, and was derived using the
“stcrreg” command in Stata, while the Cronin-Feuer
method used life table data [16] derived using the “strs”
command in Stata [14].
For multivariable analysis, the Cox proportional hazard
regression, Poisson regression (generalized linear model
with Poisson error structure), and Fine-Gray regression
were used to investigate the Indigenous survival disparity;
multivariable analysis was not available for the Cronin-
Feuer method. The same independent variables were in-
cluded in all final models: Indigenous status (Indigenous
compared to non-Indigenous); age at diagnosis (per year);
gender (female compared with male); and cancer site.
Since the effect of age at diagnosis was found to be differ-
ent for Indigenous compared with non-Indigenous
patients, an interaction term for Indigenous status by age
at diagnosis (base age 55 years) was added to the models.
For the Cox proportional hazard regression, scaled
Schoenfeld residuals were used to check if the propor-
tional hazards assumptions of each variable were satisfied.
As the proportional hazards assumption was not met for
Indigenous status, a step function of Indigenous status
with follow-up time (as annual intervals) was also
included in the model.
In the multivariable analysis for time trends, as all sub-
jects had at least 2 years of potential follow-up, the
follow-up was limited to the first 2 years after diagnosis
so that the shorter follow-up time for subjects diagnosed
late in the study period did not bias time trends. Regres-
sion models included the same terms as above, plus year
of diagnosis.
All analyses were conducted using Stata/SE 13
(StataCorp, College Station, TX). Ethics approval was
obtained from the Human Research Ethics Committee
of the Menzies School of Health Research and NT
Department of Health. Approval to use the cancer regis-
trations data was obtained from the NT Cancer Registry.
Results
There were 9,595 invasive cancer cases between 1991
and 2009 that fulfilled the study criteria (Table 2). 18.6%
were identified as Indigenous, who were more likely to
be female, younger, and live in remote regions. A higher
proportion of Indigenous (69.8%) than non-Indigenous
(46.4%) patients died during the study period.
Adjusting for age and sex, net survival (estimated
using relative survival) was lower for Indigenous than
Table 1 A summary of different cancer prognosis statistics and survival analysis methods used in this study
Prognosis statistics Using cause of death data Using life tables
Net survival (excludes competing risks) Measure Cause-specific survival Relative survival
Calculation method Kaplan-Mier Divide observed survival by expected
survival
Multivariable analysis method Cox proportional hazard model Poisson model
Crude probability (includes competing risks) Measure Crude probability of death Crude probability of death using life
table
Calculation method Fine-Gray method Cronin-Feuer method
Multivariable analysis method Fine-Gray model Nil
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non-Indigenous patients at both 1 and 5 years after diag-
nosis for breast, colorectal, and head and neck cancers
(Table 3).
The multivariable results for all cancers combined
(adjusted for cancer site) were similar for all terms
included in the model for each of the three methods:
relative survival analysis using Poisson regression; cause-
specific analysis using Cox proportional hazards regres-
sion; and competing risk analysis using Fine-Gray
regression (Tables 4 and 5). The Poisson regression, Cox
proportional hazards regression, and the Fine-Gray
regression (for cancer deaths) showed that the excess
mortality of Indigenous patients was highest in the first
year after diagnosis and decreased over time until the
fifth year, with male and older patients experiencing
higher risk of cancer death (Table 4). Age at diagnosis
had different effects for Indigenous and non-Indigenous
cases; the cancer death rate increased by 1% per year of
age for Indigenous cases and 3% per year of age for non-
Indigenous cases (Table 4). The Fine-Gray model (for
non-cancer deaths) showed that Indigenous patients
were more likely than non-Indigenous to die of non-
cancer causes and that, in contrast to cancer deaths, this
differential increased rather than decreased with time in
the first 5 years after diagnosis (Table 4, Additional
file 1: Table S3a). Remoteness of residence at time of
diagnosis was not associated with risk of either cancer or
non-cancer death for Indigenous or non-Indigenous pa-
tients and was therefore not included in all the regression
models. The results for the analysis of time trend in 2-year
survival rate were similar for all three regression models
(Table 5, Additional file 2: Table S4a); the death rate
in the first 2 years after diagnosis decreased by 3%
per diagnosis year after adjustment for Indigenous
status, sex, and age.
The measures of crude probabilities of deaths are pre-
sented as proportion of cases that have died at 5 years
after diagnosis (Table 6) from cancer and other causes.
Cancer death probabilities (for all cancers combined and
for the four individual cancer sites) were higher for
Indigenous than non-Indigenous patients 5 years after
cancer diagnosis, whether calculated by the Fine-Gray or
Cronin-Feuer methods. Non-cancer death probabilities
were also higher for Indigenous than non-Indigenous
patients for all cancers combined and for breast and
colorectal cancers, as estimated by both the Cronin-
Feuer and Fine-Gray methods. Amongst the patients
with head and neck cancers and lung cancer (both
smoking-related cancers) and colorectal cancer, the non-
cancer death probabilities estimated by Cronin-Feuer
were much lower than those estimated by the Fine-Gray
methods for the non-Indigenous, but not the Indigenous
patients. Amongst the patients with breast cancer, the
cancer and non-cancer death probabilities estimated by
Cronin-Feuer were higher than those estimated by the
Fine-Gray methods. The Indigenous disparities (in can-
cer death) estimated by the Cronin-Feuer method were
lower than those estimated by the Fine-Gray method for
all cancers except for breast cancer; the Indigenous
disparities (in non-cancer death) estimated by the
Cronin-Feuer method were higher than those estimated
by the Fine-Gray method for all cancers except for lung
cancer and head and neck cancers.
Table 2 Demographic characteristics of people diagnosed with








Age at diagnosis (%)
0 to 49 years 36.3 30.3
50 to 59 years 26.6 26.0
60 to 69 years 22.0 23.7
70 years and over 15.1 20.0




Vital Status at 31 Dec 2011 (%)
Alive 30.2 53.6
Dead 69.8 46.4
Table 3 One-year and 5-year cumulative relative survival (%) and 95% confidence interval by Indigenous status and cancer site
(age and sex adjusted), Australia NT, 2001–2009
Indigenous Non-Indigenous
Cancer site Cases One-year Five-year Cases One-year Five-year
Breast 152 87.3 (80.1–92.1) 66.4 (55.7–75.1) 954 97.7 (95.9–98.7) 86.5 (83.1–89.3)
Colorectal 96 64.3 (53.6–73.1) 40.4 (29.1–51.4) 784 84.2 (81.3–86.8) 58.4 (54.2–62.4)
Head and necka 194 54.0 (46.5–60.9) 36.0 (28.5–43.6) 514 85.7 (82.3–88.5) 63.9 (59.2–68.2)
Lunga 293 27.6 (22.5–33.0) 8.9 (5.7–12.9) 740 36.0 (32.1–39.8) 12.6 (9.9–15.6)
aSmoking-related cancers
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Discussion
This study is the first to examine the implications of
various survival methods to assess the survival inequal-
ities faced by Indigenous cancer patients in the NT, in
particular the impact of competing causes of death.
Multivariable regression using relative survival (Poisson
model), cause-specific survival (Cox regression) and
competing risk analysis (Fine-Gray model) produced
similar results. For all cancers combined, death rates
were higher for Indigenous, male and older cancer
patients for both cancer and non-cancer death. In the
absence of competing risk, Indigenous people have lower
5-year net survival than non-Indigenous people for all
three cancers (breast, colorectal, and head and neck
cancers).
Crude probability of death potentially offers a more
understandable way than net survival to communicate
cancer prognosis to patients and clinicians, showing the
different mortality risk profiles (cancer and non-cancer
death probabilities) among the Indigenous and non-
Indigenous populations, while acknowledging that
cancer patients can also die of non-cancer causes [17]. It
enables us to identify whether survival disparities are
caused by cancer, non-cancer, or both cancer and non-
cancer deaths, as well as identify the disparities in both
cancer and non-cancer deaths across time. The multivar-
iable competing risk analysis, Fine-Gray model, found
that Indigenous patients were more likely than non-
Indigenous to die of non-cancer causes and that, in
contrast to cancer deaths, this differential increased ra-
ther than decreased with time after diagnosis. Five years
after diagnosis, Indigenous cancer patients had higher
rates of non-cancer death than non-Indigenous patients
and this differential was increasing with time since
diagnosis, while there was no longer a differential in
cancer deaths. This finding suggests the need for inte-
grated chronic disease management strategies for cancer
patients, particularly for the Indigenous population with
Table 4 Regression analysis of cause-specific mortality (Cox proportional hazard regression), relative survival (Poisson regression),
and competing risk (Fine-Gray regression), all cancers combineda, Australia NT, 1991–2009
Relative survival Cause-specific Competing (due to cancers) Competing (other death)
HR (95% CI)b HR (95% CI) SHR (95% CI) SHR (95% CI)
Indigenousc
1st year after diagnosis 2.15 (1.96–2.36) 2.17 (1.98–2.38) 1.97 (1.79–2.17) 1.67 (1.16–2.42)
2nd year after diagnosis 1.35 (1.11–1.64) 1.47 (1.22–1.76) 1.53 (1.27–1.85) 2.75 (1.57–4.81)
3rd year after diagnosis 1.09 (0.79–1.52) 1.32 (1.01–1.72) 1.45 (1.11–1.90) 5.10 (2.89–8.99)
4th year after diagnosis 1.29 (0.83–1.99) 1.26 (0.87–1.80) 1.44 (1.00–2.08) 8.96 (4.60–17.47)
5th year after diagnosis 0.56 (0.25–1.28) 0.78 (0.46–1.32) 0.95 (0.56–1.62) 5.72 (2.75–11.88)
Female vs male 0.83 (0.77–0.90) 0.84 (0.78–0.90) 0.85 (0.78–0.92) 0.71 (0.54–0.93)
Age at diagnosisd
Non-Indigenous 1.03 (1.03–1.03) 1.03 (1.03–1.03) 1.03 (1.02–1.03) 1.07 (1.06–1.08)
Indigenous 1.02 (1.01–1.02) 1.01 (1.01–1.02) 1.01 (1.00–1.02) 1.05 (1.03–1.07)
aModel adjusted for cancer site (with colorectal cancer as the reference category for cancer site)
bHR hazard ratio, SHR standard hazard ratio
cApplies to the reference categories of the interaction terms (i.e., people of median age 55 years)
dPer year of age
Table 5 Regression analysis of time trend after diagnosis using cause-specific mortality (Cox proportional hazard regression), relative
survival (Poisson regression), and competing risk analysis (Fine-Gray regression), all cancers combineda, Australia NT, 1991–2009
Relative survival Cause-specific Competing (due to cancers) Competing (other death)
HR (95% CI)b HR (95% CI) SHR (95% CI) SHR (95% CI)
Indigenousc 1.99 (1.82–2.16) 2.01 (1.85–2.19) 1.94 (1.77–2.13) 2.49 (1.70–3.63)
Female vs male 0.86 (0.79–0.93) 0.84 (0.77–0.91) 0.87 (0.79–0.94) 0.74 (0.53–1.04)
Age at diagnosisd
Non-Indigenous 1.03 (1.03–1.04) 1.03 (1.03–1.04) 1.03 (1.03–1.03) 1.07 (1.06–1.08)
Indigenous 1.02 (1.01–1.02) 1.02 (1.01–1.02) 1.02 (1.01–1.02) 1.02 (1.00–1.04)
Year of diagnosis 0.97 (0.96–0.97) 0.97 (0.96–0.97) 0.97 (0.96–0.97) 0.97 (0.95–1.00)
aModel adjusted for cancer site (with colorectal cancer as the reference category for cancer site)
bHR hazard ratio, SHR standard hazard ratio
cApplies to the reference categories of the interaction terms (i.e. people of median age 55 years in 2009)
dPer year of age
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higher rate of chronic diseases comorbidities. The find-
ing also demonstrates an important advantage of the
competing risk approach over conventional relative
survival in analyzing long-term outcomes for Indigenous
cancer patients.
In the presence of competing risks, the Cronin-Feuer
method produced similar results to the Fine-Gray
method in the estimation of cancer death probability
(higher Indigenous cancer death probabilities for all
cancers) and non-cancer death probabilities (higher
Indigenous non-cancer death probabilities for all cancers
except lung cancer and head and neck cancers) 5 years
after cancer diagnosis. The Cronin-Feuer method esti-
mated much lower non-cancer death probabilities than
the Fine-Gray method for non-Indigenous patients with
head and neck cancers and lung cancer, which are both
smoking-related cancers.
Comparison of death probabilities estimated using the
Cronin-Feuer method and Fine-Gray models provides in-
sights into “external factors” affecting measures of survival
for various cancer types such as smoking-related cancers.
The death probabilities estimated using the Cronin-Feuer
method can be seen as the death probabilities that the
cancer patients were “expected to have”, in the hypothet-
ical scenario where cancer patients have the same death
risks as the general population, unaffected by “external
factors” that cancer patients experienced such as
unhealthy behaviors, access to health care, or screening
effects. The death probabilities estimated using cause of
death data and the Fine-Gray method can be seen as the
“observed death probabilities” in which cancer patients
might have different risks of death to the general popula-
tion due to various “external factors”. Therefore, higher
(or lower) non-cancer death probabilities estimated by the
Fine-Gray model imply higher (or lower) non-cancer
death risks in cancer patients than the general population.
When analyzing smoking-related cancers, caution is
required for prognosis measures calculated using gen-
eral population life tables such as relative survival
and the Cronin-Feuer method [18–20], which assume
that cancer patients have the same death risks as the
general population. This assumption is probably vio-
lated for smoking-related cancers, because smoking
increases mortality from other causes of death such
as respiratory and cardiovascular diseases, resulting in
higher non-cancer death risks in cancer patients than
the general population. Therefore, the Cronin-Feuer
method will underestimate the non-cancer death
probabilities of the patients with smoking-related
cancers if it uses the general population life tables for
the cancer patients with higher non-cancer death
risks. The results from our study support the hypoth-
esis that methods using life tables (relative survival
and Cronin-Feuer) underestimate non-cancer deaths
and overestimate cancer deaths for smoking-related
cancers for non-Indigenous patients, suggesting that
Cronin-Feuer method should be used with caution in
estimating cancer and non-cancer death probability
for non-Indigenous patients with smoking related
cancers and quantifying the Indigenous disparity for
smoking-related cancers. Our study has shown that
the Indigenous disparity in smoking-related cancer
death probabilities estimated by Cronin-Feuer method
is lower than that estimated by the Fine-Gray
method, which suggests that survival analysis methods
that use the life table such as relative survival might
underestimate the Indigenous disparity in cancer
survival for smoking-related cancers.
Table 6 Five-year cumulative probabilities of cancer and non-cancer death (%), age and sex adjusted
Cancer type Indigenous Non-Indigenous Disparity
Cronin-Feuer Fine-Gray Ratio (CF/FG) Cronin-Feuer Fine-Gray Ratio (CF/FG) CFa FGb
Cancer death probabilities All cancers 61.0 65.7 0.93 33.2 33.2 1.00 1.84 1.98
Breast 31.6 28.9 1.09 13.2 12.2 1.08 2.39 2.37
Colorectal 57.7 65.1 0.89 40.6 40.1 1.01 1.42 1.62
Head & neckc 62.5 67.7 0.92 35.8 33.6 1.07 1.75 2.01
Lungc 88.4 92.5 0.96 86.4 85.5 1.01 1.02 1.08
Other causes All cancers 6.1 4.0 1.53 3.7 3.0 1.23 1.65 1.33
Breast 10.6 4.3 2.47 4.4 2.0 2.20 2.41 2.15
Colorectal 7.6 6.6 1.15 4.4 5.3 0.83 1.73 1.25
Head & neckc 6.2 5.9 1.05 2.8 8.2 0.34 2.21 0.72
Lungc 4.0 3.0 1.33 1.6 3.9 0.41 2.50 0.77
aDisparity measured using Cronin-Feuer method (expressed as ratio of death probabilities among the Indigenous cancer cohort to the death probabilities among
the non-Indigenous cohort diagnosed with the same cancer)
bDisparity measured using Fine-Gray method
cSmoking-related cancers
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Previous studies suggested that relative survival tends
to underestimate social inequalities in cancer survival
[21–23]. Our study suggests that the Cronin-Feuer
method does underestimate Indigenous to non-Indigenous
disparities in cancer death probabilities (except for breast
cancer) while overestimating disparities in non-cancer
death probabilities (except for lung, head and neck can-
cers, which are both smoking-related cancers) after con-
sidering competing risks. Underestimation of cancer death
disparity by the Cronin-Feuer method was largest for colo-
rectal cancer and head and neck cancers. For colorectal
cancer, this underestimation was mainly due to underesti-
mation of the probability of cancer death for Indigenous
patients. For head and neck cancers, underestimation of
disparity is due to a combination of underestimation of
probability of cancer death for Indigenous patients and
overestimation of cancer death probabilities for non-
Indigenous patients. However, for breast cancer patients
the disparity in cancer deaths was similar for the two
methods; the Fine-Gray method produced lower estimates
of both cancer and non-cancer death probability than the
Cronin-Feuer method for both Indigenous and non-
Indigenous patients.
The lower estimates of cancer death probabilities of
the Fine-Gray method might indicate that cancer sur-
vival for breast cancer patients is better than expected
(calculated using life table). The lower estimates of non-
cancer death probabilities of the Fine-Gray method
might indicate lower non-cancer 5-year death risk in
breast cancer patients than the background population,
supported by the findings of another study [24] (not
specifically for Indigenous cancer patients) that breast
cancer patients have reduced risks for death (compared
to the general population) from cardiovascular disease
(SMR = 83.9), which accounts for the majority (55%) of
non-cancer deaths among cancer patients generally in
Australia; higher risks for non-cancer deaths were ob-
served for all cancer types except breast cancer and mel-
anoma. The lower than expected cancer and non-cancer
death probability for breast cancer patients may be due
to these patients having higher socioeconomic status,
which might be a protective factor of cancer and non-
cancer deaths, as indicated by the finding that breast
cancer is more common in areas of higher socioeco-
nomic status in Australia [25] (breast cancer incidence
rate was 122 per 100,000 in the highest socioeconomic
status group, compared to 103 per 100,000 in the lowest
socioeconomic status group).
Conclusion
While net survival is useful for reporting trends in
cancer survival, comparing different groups of cancer
patients and investigating the impact of various factors
on cancer treatment, crude probability of death is
important when communicating risks to patients [10]
during clinical decision making [9, 26]. Previous studies
have suggested that relative survival tends to underesti-
mate social inequalities in cancer survival; our study sug-
gests that the Cronin-Feuer method does underestimate
Indigenous to non-Indigenous disparities in cancer death
probabilities (except for breast cancer) in the presence
of competing risks. Our study also suggests that when
analyzing smoking-related cancers, caution is required
when measuring cancer survival disparity using popula-
tion life tables. Despite the limitations of the Cronin-
Feuer method [16], it is a reasonable alternative to the
Fine-Gray method for assessing the Indigenous survival
differential in the presence of competing risks when
valid and reliable subgroup-specific life tables are
available and cause of death data are unavailable or
unreliable.
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